Invited Editorial: Advantages and Limitations of FAERS in Assessing Adverse Event Reporting for Eluxadoline

Gelijkaardige items

• Drug Profile Elobixibat for the Treatment of Constipation
  door: Chedid, Victor, et al.
  Gepubliceerd in: (2018)
• A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod
  door: Yingxiu Wu, et al.
  Gepubliceerd in: (2025-11-01)
• Exploring the FDA Adverse Event Reporting System (FAERS) to Generate Hypotheses for Disease Monitoring
  door: Fang, Hong, et al.
  Gepubliceerd in: (2014)
• Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
  door: Timbrook, Tristan T., et al.
  Gepubliceerd in: (2020)
• Comparison of Brand versus Generic Antiepileptic Drug Adverse Event Reporting Rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
  door: Rahman, Md. Motiur, et al.
  Gepubliceerd in: (2017)